Vident Investment Advisory’s Kite Pharma, Inc. KITE Stock Holding History

Vident Investment Advisory’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,213	Closed	-$2.38M	–	843
2017 Q3	$2.38M	Buy	13,213 +400	+3%	+$55.7K	0.13%	252
2017 Q2	$1.33M	Sell	12,813 -5,147	-29%	-$420K	0.11%	289
2017 Q1	$1.41M	Buy	17,960 +2,992	+20%	+$185K	0.14%	283
2016 Q4	$671K	Buy	14,968 +2,064	+16%	+$101K	0.08%	318
2016 Q3	$721K	Sell	12,904 -243	-2%	-$13.5K	0.1%	312
2016 Q2	$657K	Sell	13,147 -7,319	-36%	-$360K	0.09%	340
2016 Q1	$940K	Buy	20,466 +9,494	+87%	+$460K	0.06%	354
2015 Q4	$676K	Buy	+10,972	New	+$772K	0.09%	349

Vident Investment Advisory's KITE Position: Q4 2017 in Review

Vident Investment Advisory sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 13,213 shares — an estimated $2.38M sold.

Vident Investment Advisory first reported a position in KITE in Q4 2015 and held it in 8 quarters. The position peaked at $2.38M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

Vident Investment Advisory reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
Vident Investment Advisory sold 13,213 Kite Pharma, Inc. shares in Q4 2017, an estimated $2.38M.
Vident Investment Advisory first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 8 quarters.
Vident Investment Advisory's Kite Pharma, Inc. position peaked at $2.38M in Q3 2017.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Vident Investment Advisory's 13F filing for Q4 2017, filed 15 Feb 2018.